Home › Funds › Choate Investment Advisors › ABT

Choate Investment Advisors position in ABT

ABBOTT LABORATORIES · Health Care

Choate Investment Advisors reported holding 219,937 shares of ABT (ABBOTT LABORATORIES) in its Q3 2026 13F filing — a position valued at US$21.7M, representing 0.37% of its reported portfolio and ranking #32 among its reported holdings. Choate Investment Advisors has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)219.94K sh
Reported value held$21.74M
Portfolio Weight0.37%
First reportedQ3 2023
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Choate Investment Advisors's ABT position evolved

Choate Investment Advisors first disclosed a stake in ABT in Q3 2023 at 125,965 shares (US$12.2M). The position peaked in Q4 2025 at 305,976 shares, worth US$38.3M. Across 13 filings, Choate Investment Advisors increased the stake 8 time(s), trimmed it 4 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 219,937 shares valued at US$21.7M — a reduction of -14,503 shares quarter over quarter.. Notable position changes include a 26% increase in Q4 2023 (shares rose 4% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 125.97K $12.20M New
Q4 2023 158.82K $17.48M Add
Q1 2024 175.54K $19.95M Add
Q2 2024 172.36K $17.91M Reduce
Q3 2024 178.54K $20.35M Add
Q4 2024 206.65K $23.37M Add
Q1 2025 231.99K $30.77M Add
Q2 2025 263.13K $35.79M Add
Q3 2025 279.96K $37.50M Add
Q4 2025 305.98K $38.34M Add
Q1 2026 304.22K $31.23M Reduce
Q2 2026 234.44K $21.27M Reduce
Q3 2026 219.94K $21.74M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ABT and 13F data

ABT (ABBOTT LABORATORIES) is a Health Care company. 21 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ABT

All ABT fund holders →

FAQ

How long has Choate Investment Advisors held ABT?

Choate Investment Advisors has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Choate Investment Advisors's current position in ABT?

As of Q3 2026, Choate Investment Advisors holds 219.94K shares of ABT (ABBOTT LABORATORIES), valued at $21.74M, representing 0.37% of its reported portfolio and ranking #32.

Has Choate Investment Advisors been buying or selling ABT?

In the latest 13F filing (Q3 2026), Choate Investment Advisors reduced its position in ABT. The position peaked in Q4 2025 at 305.98K shares.

Which other funds hold ABT?

Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 21 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.